Immunologic Factor – Page 43

AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval

1 year ago talkbio0Tagged ADCs, AstraZeneca, Datopotamab, Deruxtecan, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, TACSTD2 gene, Trodelvy

TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)

Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer

1 year ago talkbio0Tagged amivantamab-vmjw, Chemotherapy-free, Clinical Research, EGFR-mutated lung cancer, Lazcluze, lazertinib, MARIPOSA, Non-Small Cell Lung Carcinoma, osimertinib, Rybrevant, Survival Analysis

Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

1 year ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation

GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results

1 year ago talkbio0Tagged Asthma, Chronic Obstructive Airway Disease, interleukin-5, mepolizumab, Monoclonal Antibodies, Nucala, Phase 3 Clinical Trials, SmithKline Beecham

GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.

ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges

1 year ago talkbio0Tagged Agonist, Anktiva, Approved, Cancer Therapeutic Procedure, financial troubles, ImmunityBio, Immunotherapy, Interleukin-15, United States Food and Drug Administration

ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy

Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster

1 year ago talkbio0Tagged Immune response, Lyme Disease, Pfizer, Phase 2 Trials, Submission, United States Food and Drug Administration, Vaccines, Valneva, VLA15

Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission

Enhancing Flu Vaccine Uptake in the Post-Pandemic Era: Strategies and Insights

1 year ago talkbio0Tagged Health Personnel, historical period, Post-Pandemic, public health strategies, Uptake, Urinary hesitation, Vaccination, Vaccines

flu vaccine uptake, post-pandemic era, vaccine hesitancy, public health strategies, healthcare providers, influenza vaccination

FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use

1 year ago talkbio0Tagged authorization, COVID19 (disease), Emergency Situation, JN.1, Novavax, protein-based vaccine, United States Food and Drug Administration, Vaccines, Variant

Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant

Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3

1 year ago talkbio0Tagged Bacterial Infections, development aspects, Phase 3 program, pneumococcal conjugate, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases

Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15

1 year ago talkbio0Tagged development aspects, Lyme Disease, Pfizer, Tick-Borne Diseases, Vaccines, Valneva, VLA15

Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases